Welcome to the Right Decision Service (RDS) newsletter for April 2024.
Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May. If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.
Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.
Thank you for your patience and understanding while we achieve a full resolution.
A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.
The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.
The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.
Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.
These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.
Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.
Figure 1: Impact of RDS on direct delivery of care
Key figures
Figure 2 shows RDS impact to date on delivery of health and care services
Key figures
These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.
Saving time and money
Quality assurance and governance
Service innovation and workforce development
A few examples of toolkits published to live in the last month:
Some of the toolkits the RDS team is currently working on:
Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.
Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions. We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.
Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine. The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.
With kind regards
Right Decision Service team
Healthcare Improvement Scotland
This toolkit is based on SIGN guideline 155: Pharmacological management of migraine. It includes evidence-based recommendations for best practice in the acute and prophylactic pharmacological management of adults with migraine episodic or chronic migraine. Medication-overuse headache is also covered. Studies of children with migraine were not included, however the recommendations could be considered for treating adolescents with migraine.
The toolkit will be of interest to healthcare professionals in primary and secondary care, including general practitioners, headache nurses, neurologists, out-of-hours clinicians, pharmacists, and patients with migraine.
The application is available as a website and as downloadable mobile applications, via the following link:
Online http://signdecisionsupport.uk and http://rightdecisions.scot.nhs.uk
This software is an informational and educational resource. It is not a medical device as defined by the Medical Devices Directive.
SIGN (Scottish Intercollegiate Guidelines Network): SIGN was formed in 1993. Its objective is to improve the quality of health care for patients in Scotland by reducing variation in practice and outcome, through the development and dissemination of national clinical guidelines containing recommendations for effective practice based on current evidence.
The membership of SIGN includes all the medical specialties, nursing, pharmacy, dentistry, professions allied to medicine, patients, health service managers, social services, and researchers. The work of SIGN is supported by an Executive.
SIGN is part of the Evidence Directorate of Healthcare Improvement Scotland and core funding from Healthcare Improvement Scotland supports the SIGN Executive, and expenses and costs associated with guideline development projects. SIGN is editorially independent from Healthcare Improvement Scotland and the Scottish Government which ultimately funds Healthcare Improvement Scotland.
SIGN Guideline 155 was published in February 2018 and updated in 2022 and 2023. The app will be updated if any further updates are made to the guideline.
Technical maintenance and updating of the app is carried out by Tactuum Ltd and funded through the National Decision Support Programme led by the Digital Health and Care Institute.
The content within this app/ website is based on current evidence and best practice, however it is intended to be applied alongside sound clinical judgement. As such, Healthcare Improvement Scotland is not responsible or liable for any diagnosis or management decision made on the basis of the information provided via this app/website.
Use of this app within patient care settings should always be in accordance with local policies and guidance with regard to clinical practice and mobile device usage.
Healthcare Improvement Scotland is not responsible for the content of any external websites listed, nor do they endorse any commercial product or service mentioned or advised on in any of these websites.
All use of this resource is subject to Scots law and the jurisdiction of the Scottish courts and is subject to this disclaimer. Any views given on the app/website are not necessarily those of Healthcare Improvement Scotland or anyone connected with us.
Copyright information for the two sources of content within this app/website is shown below.
Scottish Intercollegiate Guidelines Network (SIGN). SIGN 155: Pharmacological management of migraine. Edinburgh: SIGN; 2023. [cited 04 Apr 2023] Available from: www.sign.ac.uk/our-guidelines/pharmacological-management-of-migraine/
Copyright of this guideline is retained by SIGN. Users may download or print copies for their own use and may photocopy guidelines for the purpose of implementation.
This review is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence. This allows for the copy and redistribution of SIGN guidelines as long as SIGN is fully acknowledged and given credit. The material must not be remixed, transformed or built upon in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/.
Please cite the guideline as: Scottish Intercollegiate Guidelines Network (SIGN). Guideline title. Edinburgh: SIGN; Year. [cited dd mmm yyyy]. Available from URL: http://www.sign.ac.uk.
Users wishing to use reproduce or republish SIGN material for commercial purposes must seek prior approval for reproduction in any medium by completing the form at https://www.sign.ac.uk/media/1392/sign-copyright-request.pdf
Applicants for such permission should be aware that:
Ailsa Stein - Programme Manager, SIGN. ailsa.stein@nhs.scot
Kirsty Littleallan - Administrative Officer, SIGN. kirsty.littleallan@nhs.scot
Content has been checked for accessibility in line with the relevant RDS standard operating procedure.
The content in this toolkit has been developed by the SIGN guideline group for SIGN 155: Pharmacological management of migraine
Content has been reviewed and approved in line with the SIGN editorial governance process.
Final content was signed off by the SIGN Programme Lead.
The content will be considered for update 3 years from publication. Any minor updates brought to the attention will be dealt with on an "as needed" basis.
Updates will be reviewed and approved in line with the SIGN editorial governance process.
Content will be updated using the guideline development processes outlined in the SIGN methodology manual, SIGN 50: a guideline developer's handbook.
The content was reviewed by the clinicians and people with lived experience on the guideline development group.
The SIGN guideline was available for peer review in June 2017. An update to the guideline was peer reviewed in June 2022. All comments received were addressed and responses published on the SIGN website.
The guideline was reviewed by clinical experts from SIGN Council as part of the editorial process.
This toolkit is based on SIGN guideline 155: Pharmacological management of migraine, which includes details on how the guideline was produced. Further information on SIGN methodology is available from SIGN 50: a guideline developer's handbook
The content of this toolkit was reviewed by the SIGN editorial team and signed off by the SIGN Programme Lead.
The email for the SIGN Programme Manager is available in the "Key contacts" section above and can be used to highlight any feedback or complaints.
Any messages received through the RDS Feedback form will also be forwarded to the Programme Manager.
The Programme Manager will address the feedback. If it requires significant amendments, it will be referred to the SIGN senior management team for consideration for the SIGN work programme.
The toolkit has been risk assessed, and mitigations put in place where required.
Prior to publication the toolkit was user tested by the guideline development group.
Pharmacological management of migraine (SIGN)